Are you suffering from symptoms of Ulcerative colitis or Crohn's disease? Is your disease still active? If so, the Baylor Scott & White IBD Center has a number of ongoing research studies that may benefit you.
The Center conducts clinical trials of medications that hold the promise of improving the health of patients with Ulcerative Colitis or Crohn's Disease.
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis c
A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
A Phase 3, Multicenter, Open Label-Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration
A Phase 2b Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy
If you would like to learn more please contact:
Themistocles Dassopoulos, M.D.Baylor Scott & White Center for Inflammatory Bowel Diseases(469) 800-7180
Christina PodiasBaylor Research InstituteDallas Clinical Trials OfficeClinical Research Coordinator 214-818-9688